Skip to main content

Histogen, Inc. (HSTO)

NASDAQ: HSTO · Delayed Price · USD
0.800
+0.009 (1.15%)
After-hours:Sep 21, 2021 4:20 PM EDT
0.791
0.008 (1.01%)
At close: Sep 21, 4:00 PM
Market Cap33.80M
Revenue (ttm)1.41M
Net Income (ttm)-14.73M
Shares Out37.20M
EPS (ttm)-0.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume331,070
Open0.800
Previous Close0.783
Day's Range0.770 - 0.809
52-Week Range0.743 - 2.410
Betan/a
Analystsn/a
Price Target2.70 (+241.4%)
Est. Earnings DateNov 10, 2021

About HSTO

Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of ...

IndustryBiotechnology
CEOSteven Mento
Employees19
Stock ExchangeNASDAQ
Ticker SymbolHSTO
Full Company Profile

Financial Performance

In 2020, Histogen's revenue was $2.06 million, a decrease of -82.02% compared to the previous year's $11.45 million. Losses were -$18.77 million, 532.8% more than in 2019.

Financial Statements

News

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols:AVIRNRBONVIVPRVBSYN
1 week ago - InvestorPlace

Best Penny Stocks To Buy Under $1 Right Now? 5 To Watch In September

Red hot penny stocks to watch and YES all are under $1 right now. The post Best Penny Stocks To Buy Under $1 Right Now?

Other symbols:CEISONN
2 weeks ago - PennyStocks

Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

3 weeks ago - GlobeNewsWire

Histogen Shares Additional Emricasan Data From COVID-19 Study

Histogen Inc (NASDAQ: HSTO) and its partner Amerimmune LLC have announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients. As previously reported, emricasan...

1 month ago - Benzinga

Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19...

Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression

1 month ago - GlobeNewsWire

Histogen Reports Second Quarter 2021 Earnings and Provides Business Update

Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates

1 month ago - GlobeNewsWire

Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

1 month ago - GlobeNewsWire

Reddit Penny Stocks to Buy? 7 You Need to Know About In July

Looking for the best penny stocks to watch in July? Check these 7 out for your list The post Reddit Penny Stocks to Buy?

Other symbols:ACSTGOEDGSATRGLSSENS
2 months ago - PennyStocks

Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptoma...

Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events

2 months ago - GlobeNewsWire

Histogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

3 months ago - GlobeNewsWire

Histogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

3 months ago - GlobeNewsWire

Histogen Reports First Quarter 2021 Earnings and Provides Business Update

Strengthened Balance Sheet with $20.8 Million of Gross Proceeds from Financing and Warrant Exercises

4 months ago - GlobeNewsWire

Histogen Appoints Rochelle Fuhrmann to Board of Directors

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...

5 months ago - GlobeNewsWire

Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients

Topline Results Expected in the Second Quarter of 2021 Topline Results Expected in the Second Quarter of 2021

6 months ago - GlobeNewsWire

Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises

6 months ago - GlobeNewsWire

Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham-Bannister, Ph.D.

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...

6 months ago - GlobeNewsWire

Histogen to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the ...

6 months ago - GlobeNewsWire

Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the b...

8 months ago - GlobeNewsWire

DLA Piper advises Histogen in its US$14 million upsized public offering

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that...

8 months ago - PRNewsWire

Histogen Announces Closing of $14.0 Million Upsized Public Offering

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natura...

8 months ago - GlobeNewsWire

Histogen Announces Pricing of $14.0 Million Upsized Public Offering

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natura...

8 months ago - GlobeNewsWire

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publi...

1 year ago - GlobeNewsWire

Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the ...

1 year ago - GlobeNewsWire

The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. w...

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockho...

1 year ago - GlobeNewsWire